Reduction in functional antibody activity against Streptococcus pneumoniae in vaccinated elderly individuals highly correlates with decreased IgG antibody avidity

Clinical Infectious Diseases

Volumn 29, Issue 2, 1999, Pages 281-288

  Romero Steiner, Sandra ^a,b   Musher, Daniel M ^a,b   Cetron, Marty S ^a,b   Pais, Lorna B ^a,b   Groover, Jean E ^a,b   Fiore, Anthony E ^a,b   Plikaytis, Brian D ^a,b   Carlone, George M ^a,b  

^a NATIONAL CENTER FOR EMERGING AND ZOONOTIC INFECTIOUS DISEASES   (United States)

^b MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN G ANTIBODY; PNEUMOCOCCUS VACCINE;

ADULT; AGED; AGING; ANIMAL MODEL; ANTIBODY DETECTION; ANTIBODY TITER; ANTIGEN ANTIBODY COMPLEX; ARTICLE; BACTERIAL PNEUMONIA; BINDING AFFINITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MALE; MOUSE; NONHUMAN; PNEUMONIA; PRIORITY JOURNAL; STREPTOCOCCUS PNEUMONIAE; VACCINATION;

EID: 0032776804     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/520200     Document Type: Article

References (35)

1. 1. Fein AM. Pneumonia in the elderly: special diagnostic and therapeutic considerations. Med Clin North Am 1994;78:1015-33.
2. 2. Marrie TJ. New aspects of old pathogens of pneumonia. Med Clin North Am 1994;78:987-95.
3. 3. Breiman RF, Butler JC, Tenover FC, Elliott JA, Facklam RR. Emergence of drug-resistant pneumococcal infections in the United States. JAMA 1994;271:1831-5.
4. 4. Centers for Disease Control and Prevention. Prevention of pneumococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 1997;46(RR-8):1-24.
5. 5. Centers for Disease Control and Prevention. Defining the public health impact of drug-resistant Streptococcus pneumoniae: report of a working group. MMWR Morb Mortal Wkly Rep 1996;45(RR-1):1-20.
6. 6. Centers for Disease Control and Prevention. Pneumococcal and influenza vaccination levels among adults aged ≥65 years - United States, 1995. MMWR Morb Mortal Wkly Rep 1997;46(39):913-9.
7. 7. Sims RV, Steinmann WC, McConville JH, King LR, Zwick WC, Schwartz JS. The clinical effectiveness of polyvalent pneumococcal vaccine in the elderly. Ann Intern Med 1988;108:653-7.
8. 8. Butler JC, Breiman RF, Campbell JF, Lipman HB, Broome CV, Facklam RR. Pneumococcal polysaccharide vaccine efficacy: an evaluation of current recommendations. JAMA 1993;270:1826-31.
9. 9. Stein BE. Vaccinating elderly people: protecting from avoidable disease. Drugs Aging 1994;5:242-53.
10. 10. Wenger JD, Steiner SR, Pais LB, et al. Laboratory correlates for protective efficacy of pneumococcal vaccines: how can they be identified and validated? [abstract G37]. In: Program and abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1996:150.
11. 11. Musher DM, Luchi MJ, Watson DA, Hamilton R, Baughn RE. Pneumococcal polysaccharide vaccine in young adults and older bronchitics: determination of IgG responses by ELISA and the effect of adsorption of serum with non-type-specific cell wall polysaccharide. J Infect Dis 1990:161:728-35.
12. 12. Musher DM, Groover JE, Rowland JM, et al. Antibody to capsular polysaccharides of Streptococcus pneumoniae: prevalence, persistence, and response to revaccination. Clin Infect Dis 1993;17:66-73.
13. 13. Ruben FL, Uhrin M. Specific immunoglobulin-class antibody responses in the elderly before and after 14-valent pneumococcal vaccine. J Infect Dis 1985;151:845-9.
14. 14. Sankilampi U, Honkanen PO, Bloigu A, Herva E, Leinonen M. Antibody response to pneumococcal capsular polysaccharide vaccine in the elderly. J Infect Dis 1996;173:387-93.
15. 15. Mufson MA, Krause HE, Schiffman G. Long-term persistence of antibody following immunization with pneumococcal polysaccharide vaccine. Proc Soc Exp Biol Med 1983;173:270-5.
16. 16. Roghmann KJ, Tabloski PA, Bently DW, Schiffman G. Immune response of elderly adults to pneumococcus: variation by age, sex, and functional impairment. J Gerontol 1987;42:265-70.
17. 17. Landesman SH, Schiffman G. Assessment of the antibody response to pneumococcal vaccine in high-risk populations. Rev Infect Dis 1981;3(suppl):S184-96.
18. 18. Hedlund JU, Mats EK, Örtqvist AB, Henrichsen J. Antibody response to pneumococcal vaccine in middle-aged and elderly patients recently treated for pneumonia. Arch Intern Med 1994;154:1961-5.
19. 19. Shapiro ED, Berg AT, Austrian R, et al. The protective efficacy of polyvalent pneumococcal polysaccharide vaccine. N Engl J Med 1991;325:1453-60.
20. 20. Musher DM, Chapman AJ, Goree A, Jonsson S, Briles D, Baughn RE. Natural and vaccine-related immunity to Streptococcus pneumoniae. J Infect Dis 1986;154:245-56.
21. 21. Fiore AE, Iverson C, Messmer T, et al. Outbreak of pneumonia in a long-term care facility: antecedent human parainfluenza virus 1 infection may predispose to bacterial pneumonia. J Am Geriatr Soc 1998;46:1112-7.
22. 22. Quartaert SA, Kirch CS, Quackenbush Weidl LJ, et al. Assignment of weight-based antibody units to a human antipneumococcal standard reference serum, lot 89-S. Clin Diagn Lab Immunol 1995;2:590-7.
23. 23. Romero-Steiner S, LiButti D, Pais LB, et al. Standardization of an opsonophagocytic assay for the measurement of functional antibody activity against Streptococcus pneumoniae using differentiated III.-60 cells. Clin Diagn Lab Immunol 1997;4:415-22.
24. 24. Antilla M, Eskola J, Ǎhman H, Käyhty H. Avidity of IgG for Streptococcus pneumoniae type 6B and 23F polysaccharides in infants primed with pneumococcal conjugates and boosted with polysaccharide or conjugate vaccines. J Infect Dis 1998;177:1614-21.
25. 25. Granoff DM, Maslanka SE, Carlone GM, et al. A modified enzyme-linked immunosorbent assay for measurement of antibody responses to meningococcal C polysaccharide that correlate with bactericidal responses. Clin Diagn Lab Immunol 1998;5:479-85.
26. 26. MacDonald RA, Hosking CS, Jones CL. The measurement of relative antibody affinity by ELISA using thiocyanate elution. J Immunol Methods 1988;106:191-4.
27. 27. Musher DM, Johnson B Jr, Watson DA. Quantitative relationship between anticapsular antibody measured by enzyme-linked immunosorbent assay or radioimmunoassay and protection of mice against challenge with Streptococcus pneumoniae serotype 4. Infect Immun 1990;58:3871-6.
28. 28. Rubins JB, Puri AKG, Loch J, et al. Magnitude, duration, quality, and function of pneumococcal vaccine responses in elderly adults. J Infect Dis 1998;178:431-40.
29. 29. Konradsen HB. Quantity and avidity of pneumococcal antibodies before and up to 5 years after pneumococcal vaccination of elderly persons. Clin Infect Dis 1995;21:616-20.
30. 30. Powers DC, Anderson EL, Lottenbach K, Mink CAM. Reactogenicity and immunogenicity of a protein-conjugated pneumococcal oligosaccharide vaccine in older adults. J Infect Dis 1996;173:1014-8.
31. 197-conjugated pneumococcal oligosaccharide vaccines in young and elderly adults. Infect Immun 1997;65:242-7.
32. 32. Garg M, Luo W, Kaplan AM, Bondada S. Cellular basis of decreased immune-responses to pneumococcal vaccines in aged mice. Infect Immun 1996;64:4456-62.
33. 33. Ito Y, Ponnappan U, Lipschitz DA. Excess formation of lysophosphatidic acid with age inhibits myristic acid-induced superoxide anion generation in intact human neutrophils. FEBS Lett 1996;394:149-52.
34. 34. Fulop T Jr, Fouquet C, Allaire P, et al. Changes in apoptosis of human polymorphonuclear granulocytes with aging. Mech Aging Dev 1997;96:15-34.
35. 35. Bureau for the Census. Population estimates/nation/intfile2-1.txt. Worldwide web site http://www.census.gov. Accessed 14 April 1998.